Protein– tag –
-
Biotech VC Funding Reaches $20.1 Billion in H1 2026 as Companies Secure Significant Capital for Early Development Stages
BioBucks / Fierce Biotech USA Overview In the first half of 2026, biotech VC funding totaled $20.1 billion, with several companies completing major financing rounds. Vaderis Therapeutics secured $152 million in Series B for a Phase III t... -
DCAT Report: 2026 CDMO Market Sees Major M&A and Capital Investments, with Samsung Biologics to Acquire PolyPeptide Group for $1.8 Billion
DCAT Value Chain Insights USA Overview According to a DCAT Value Chain Insights report, the 2026 CDMO market is witnessing a surge in peptide-based drug development, accompanied by significant M&A and capital investments. Samsung Bio... -
Serina Therapeutics Highlights POZ Platform’s Potential to Enhance Efficacy and Safety of Small Molecule, RNA, and ADC Therapies
BioSpace USA Overview Serina Therapeutics announced its Q2 2026 financial and business updates, emphasizing the advancement of its wholly-owned pipeline for neurological and other indications, powered by its proprietary POZ Platform™. Th... -
Johns Hopkins Medicine Unveils Synthetic mRNA Platform for Faster, More Efficient Next-Gen Therapeutics
Johns Hopkins Medicine USA Overview Scientists at Johns Hopkins Medicine have announced the development of an experimental synthetic mRNA-based platform that holds the potential to deliver next-generation mRNA therapeutics for infectious... -
Nagoya University and Fujifilm Jointly Develop Novel LNP Delivery System for Enhanced Cyclic RNA Therapeutics
EurekAlert! Japan Overview Researchers from Nagoya University and Fujifilm have jointly developed a novel lipid nanoparticle (LNP) delivery system designed for efficient and stable intracellular delivery of circular RNA (cirRNA), a promi... -
FDA Grants Accelerated Approval to BMS’s Zenbexus for Multiple Myeloma in Combination with Daratumumab
U.S. Food and Drug Administration (FDA) USA Overview The U.S. FDA has granted accelerated approval to Bristol Myers Squibb's (BMS) Zenbexus (iberdomide), a novel CELMoD (cereblon E3 ligase modulator), for the treatment of multiple myelom... -
bioRxiv Preprint Unveils ELDR-Glo: A Genetically-Encoded Fluorescent Biosensor for Measuring Time Since Last Cell Cycle and Quiescence Depth
bioRxiv USA Overview A preprint on bioRxiv introduces ELDR-Glo, a genetically-encoded fluorescent biosensor designed to estimate relative cell age or the time elapsed since the last cell cycle. This biosensor integrates replication-coupl... -
Axoft Secures $55M for Ultra-Soft Brain Implants, Peel Therapeutics Nabs $20M for Anti-Cancer Nanoparticles in Series A Funding
Acquirezy USA Overview US nanotechnology companies Axoft and Peel Therapeutics have secured significant Series A funding rounds totaling $75 million between April and May 2026. Axoft raised $55 million for its ultra-soft brain implants d... -
Precision Lipid Nanoparticles Target Solid Tumors, Spare Healthy Tissue; University of Tokyo System Achieves 10x Concentration
KU Leuven Belgium Overview Researchers at Belgium's Leuven University have engineered novel lipid nanoparticles (LNPs) for targeted chemotherapy in solid tumors. These LNPs selectively bind to protein markers on malignant cells, preventi... -
Nanotoxicology Research Deepens Understanding of Nanomaterial Biocompatibility, Illuminating Surface Modification’s Impact on In Vivo Dynamics
PubMed (ResearchGate) USA Overview Nanotoxicology has evolved as a critical discipline for assessing the safety of engineered nanostructures, highlighting the importance of evaluating exposure routes. Recent research reveals that nanopar...
